# PRA-216 COPD Safety and Biomarker Study

> **NCT07730281** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Prana Therapies Inc** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** PRA-216
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07730281
- **Lead sponsor:** Prana Therapies Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730281, "PRA-216 COPD Safety and Biomarker Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*